Advertisement

Clinical and Translational Oncology

, Volume 19, Issue 9, pp 1107–1116 | Cite as

Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer

  • S. Hou
  • P. Du
  • P. Wang
  • C. Wang
  • P. LiuEmail author
  • H. LiuEmail author
Research Article

Abstract

Background

Ovarian cancer is the most lethal gynecologic malignancy worldwide with surgery as the only curative treatment. Long-term overall survival (OS) of ovarian cancer is far from satisfactory, even though significant improvement has been made in post-operative chemotherapy. One of the most important death cause is the chemoresistance due to consecutive chemotherapy. Therefore, understanding the molecular mechanisms involved in ovarian cancer development and identification of novel therapeutic targets are urgently required.

Methods

Immunohistochemical (IHC) staining was used to explore the expression pattern of mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) in tumor tissues from 138 epithelial ovarian cancer (EOC) patients. Clinicopathological data were subjected to Kaplan–Meier survival and Cox multivariate analyses to evaluate the prognostic value of MNK1 in EOC. Overexpression and silencing procedures were performed on OVCAR-5 cells to investigate the mechanisms of MNK1 in regulating EOC development. The anti-tumor effects of CGP57380, a specific MNK inhibitor, were examined by cell viability assay.

Results

Higher MNK1 expression showed significant relationship with advanced FIGO stage and positive lymph node metastasis of EOC. Univariate and multivariate analyses revealed that MNK1 was an independent prognostic factor for OS of EOC patients. In vitro study demonstrated that MNK1 can promote cell proliferation through regulating the phosphorylation level of eukaryotic initiation factor 4E. In addition, inhibition of MNK1 by CGP57380 significantly down-regulated the OVCAR-5 cell viability.

Conclusion

High MNK1 expression in EOC tissues indicates poor clinical outcomes, and MNK1 can act as a potential target for novel chemotherapy development towards EOC.

Keywords

EIF4E Epithelial ovarian cancer Inhibitor MNK1 Prognosis 

Notes

Compliance with ethical standards

Ethics

Written informed consents were obtained from all the patients. The design of this study is in accordance with the guidelines of the CONSORT Statement (http://www.consort-statement.org/) for research involving human participants.

Conflict of interest

The authors have no conflicts of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107.CrossRefPubMedGoogle Scholar
  2. 2.
    Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiogr Rev Publ Radiol Soc N Am Inc. 2011;31(3):625–46. doi: 10.1148/rg.313105066.Google Scholar
  3. 3.
    Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203. doi: 10.3322/caac.20113.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, et al. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2011;21(5):877–84. doi: 10.1097/IGC.0b013e31821a62dd.CrossRefGoogle Scholar
  5. 5.
    Hay N. Mnk earmarks eIF4E for cancer therapy. Proc Natl Acad Sci USA. 2010;107(32):13975–6. doi: 10.1073/pnas.1008908107.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci J Virtual Libr. 2008;13:5359–73.CrossRefGoogle Scholar
  7. 7.
    Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA. 2010;107(32):14134–9. doi: 10.1073/pnas.1005320107.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA. 2010;107(32):13984–90. doi: 10.1073/pnas.1008136107.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232–7. doi: 10.1101/gad.1604407.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24(15):6539–49. doi: 10.1128/mcb.24.15.6539-6549.2004.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bell JB, Eckerdt F, Alley K, Magnusson LP, Hussain H, Bi Y, et al. MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. Mol Cancer Res MCR. 2016. doi: 10.1158/1541-7786.mcr-16-0172.Google Scholar
  12. 12.
    Wheater MJ, Johnson PW, Blaydes JP. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther. 2010;10(7):728–35. doi: 10.4161/cbt.10.7.12965.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007;129(6):1065–79. doi: 10.1016/j.cell.2007.03.052.CrossRefPubMedGoogle Scholar
  14. 14.
    Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, et al. The Mnks are novel components in the control of TNFα biosynthesis and phosphorylate and regulate hnRNP A1. Immunity. 2005;23(2):177–89. doi: 10.1016/j.immuni.2005.06.009.CrossRefPubMedGoogle Scholar
  15. 15.
    O’Loghlen A, Gonzalez VM, Salinas M, Martin ME. Suppression of human Mnk1 by small interfering RNA increases the eukaryotic initiation factor 4F activity in HEK293T cells. FEBS Lett. 2004;578(1–2):31–5. doi: 10.1016/j.febslet.2004.10.063.CrossRefPubMedGoogle Scholar
  16. 16.
    Welnowska E, Castello A, Moral P, Carrasco L. Translation of mRNAs from vesicular stomatitis virus and Vaccinia virus is differentially blocked in cells with depletion of eIF4GI and/or eIF4GII. J Mol Biol. 2009;394(3):506–21. doi: 10.1016/j.jmb.2009.09.036.CrossRefPubMedGoogle Scholar
  17. 17.
    Bramham CR, Jensen KB, Proud CG. Tuning Specific Translation in Cancer Metastasis and Synaptic Memory: Control at the MNK–eIF4E Axis. Trends Biochem Sci. 2016;41(10):847–58. doi: 10.1016/j.tibs.2016.07.008.CrossRefPubMedGoogle Scholar
  18. 18.
    Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42. doi: 10.1038/nature10098.CrossRefPubMedGoogle Scholar
  19. 19.
    Jung H, Gkogkas CG, Sonenberg N, Holt CE. Remote control of gene function by local translation. Cell. 2014;157(1):26–40. doi: 10.1016/j.cell.2014.03.005.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Jones RM, MacDonald ME, Branda J, Altherr MR, Louis DN, Schmidt EV. Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. Somat Cell Mol Genet. 1997;23(3):221–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 1999;18(1):270–9. doi: 10.1093/emboj/18.1.270.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997;16(8):1909–20. doi: 10.1093/emboj/16.8.1909.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16(12):1472–87. doi: 10.1101/gad.995802.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428(6980):332–7. doi: 10.1038/nature02369.CrossRefPubMedGoogle Scholar
  25. 25.
    Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review). Int J Oncol. 2002;21(3):461–8.PubMedGoogle Scholar
  26. 26.
    Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Roske A, et al. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep. 2008;20(6):1409–17.PubMedGoogle Scholar
  27. 27.
    Choi CH, Lee JS, Kim SR, Lee YY, Kim CJ, Lee JW, et al. Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol. 2011;137(3):463–9. doi: 10.1007/s00432-010-0902-z.CrossRefPubMedGoogle Scholar
  28. 28.
    Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. doi: 10.1056/NEJMoa1105535.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Department of PharmacologyYidu Central Hospital of Weifang Affiliated to Weifang Medical UniversityWeifangChina
  2. 2.Department of Plastic SurgeryYidu Central Hospital of Weifang Affiliated to Weifang Medical UniversityWeifangChina
  3. 3.Department of Pain TreatmentQingzhou Hospital of Traditional Chinese MedicineWeifangChina
  4. 4.Department of Reproductive CenterAffiliated Hospital of North Sichuan Medical CollegeNanchongChina
  5. 5.Department of Burn and Plastic SurgeryQilu Hospital Affiliated to Shandong UniversityJinanChina
  6. 6.Department of General SurgeryQilu Hospital Affiliated to Shandong UniversityJinanChina

Personalised recommendations